文献速递膀胱癌与上尿路尿路上皮癌

肥胖悖论:体重指数与糖尿病对接受卡介苗治疗的非肌层浸润性膀胱癌患者的影响

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
PubMed 文献 · BJU Int · 2020-12-05

本研究回顾性分析579例接受卡介苗(BCG)诱导治疗的非肌层浸润性膀胱癌(NMIBC)患者,中位随访4.6年。结果显示超重和肥胖患者的无进展生存(PFS)、癌症特异性生存(CSS)和总生存(OS)均改善,而糖尿病与更差的无复发生存(RFS)相关。所用药物与结局无关。结论支持膀胱癌中存在肥胖悖论。

要点

  • 超重/肥胖与BCG治疗的NMIBC患者PFS、CSS和OS改善相关。
  • 糖尿病与BCG治疗后无复发生存(RFS)更差相关。
  • 阿司匹林、他汀、二甲双胍和β受体阻滞剂与结局无关。

核心结论

  • 升高的BMI与接受BCG免疫治疗的NMIBC患者结局改善相关,而糖尿病患者复发风险增加,支持潜在的肥胖悖论。

研究设计与样本

  • 经机构审查委员会批准的数据库回顾性研究,纳入至少完成一个BCG诱导疗程的NMIBC患者579例,中位随访4.6年。

主要发现

  • 90%患者为高级别疾病,47.2%为临床T1期;75.7%超重或肥胖,18%有糖尿病。
  • 超重和肥胖患者PFS、CSS和OS改善;糖尿病与更差RFS相关;阿司匹林、他汀、二甲双胍和β受体阻滞剂使用与结局无关。

关键数值与推荐

  • 超重或肥胖占75.7%,糖尿病占18%;阿司匹林、他汀、二甲双胍和β受体阻滞剂使用率分别为34%、42%、11%和29%。

临床怎么用

  • 对于接受BCG治疗的NMIBC患者,应关注BMI和糖尿病状态,糖尿病可能增加复发风险,需个体化风险评估和咨询。

局限性

  • 回顾性单中心数据库研究,可能存在选择偏倚和未测量混杂因素;需进一步验证机制和全球患者评估的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate if the obesity paradox, wherein obesity portends worse overall prognosis for a disease but improved outcomes for patients receiving immunotherapy, exists for patients receiving bacillus Calmette-Guérin (BCG) in a contemporary cohort. PATIENTS AND METHODS: We performed an Institutional Review Board-approved database review to identify patients with non-muscle-invasive bladder cancer (NMIBC) completing at least an induction course of BCG. Clinicopathological variables collected included: body mass index (BMI), medications, and diabetes mellitus (DM). Outcomes of interest included: recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Univariate and multivariate modelling were used to evaluate the association between outcomes and clinical factors. RESULTS: A total of 579 patients (median follow-up 4.6 years) received BCG induction for NMIBC; 90% had high-grade disease (47.2% clinical stage T1). In all, 75.7% of patients were overweight or obese and 18% had DM. Aspirin, statins, metformin and β-blockers were used in 34%, 42%, 11%, and 29% of patients, respectively. Overweight and obese patients had improved PFS, CSS and OS. DM was associated with worse RFS. Medications of interest had no association with outcomes. CONCLUSION: Elevated BMI is associated with improved outcomes in patients with NMIBC treated with BCG immunotherapy. Patients with DM are at increased risk of recurrence. These findings support a potential obesity paradox in bladder cancer. Evaluation of the underlying mechanism and the role of global patient assessment, counselling, and risk factor modification are warranted.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Brooks NA, Kokorovic A, Xiao L, et al. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. 2020. PMID: 33210440. doi:10.1111/bju.15296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。